Autoantibodies in Chinese patients with chronic hepatitis B: Prevalence and clinical associations

Table 1 Demographic and clinical features, biochemical parameters and response to antivirus treatment in chronic hepatitis B

	All patients (n = 325)
Male/female	201/124
Age (yr)	43.44 ± 16.19
Associated immune disease1n (%)	8 (2.4)
Cirrhosis	206 (63.4)
Hepatoma	38 (11.7)
Duration of HBsAg pos. n (%)	140 cases
1-5 yr	35 (25.0)
6-10 yr	25 (17.9)
11-15 yr	34 (24.3)
16-20 yr	28 (20.0)
> 20 yr	18 (12.9)
HBeAg2	147/266 (43.3)
AST (U/L)	145.10 ± 96.79
ALT (U/L)	126.51 ± 100.15
ALP (U/L)	121.08 ± 74.54
GGT (U/L)	73.43 ± 62.52
IgA (g/L)	3.24 ± 2.67
IgG (g/L)	14.73 ± 5.58
IgM (g/L)	1.37 ± 1.32
γ-globulin (g/L)	20.1 ± 7.38
Liver biopsy	31 cases
Staging and grading3n (%)
G1S1	5 (16.1)
G1S2	3 (9.7)
G1S3	1 (3.2)
G2S1	3 (9.7)
G2S2	6 (19.4)
G2S3	2 (6.5)
G2S4	2 (6.5)
G3S2	3 (9.7)
G3S3	4 (12.9)
G4S4	2 (6.5)
Anti-viral treatment response evaluation4n (%)	72 cases
Virological non-responders	6 (8.3)
Virological responders	66 (91.7)

¹Hashimoto’s thyroiditis and type 1 diabetes mellitus: 1 case each; hypothyroidism: 2 cases; probable autoimmune hepatitis: 4 cases;

²Hepatitis B e-antigen statuses were identified in 266 cases;

³The Scheuer system was used to score necroinflammatory activity and fibrosis/cirrhosis;

⁴The virological response was defined as hepatitis B virus DNA concentration of less than 2000 IU/mL at 12 mo after nucleoside/nucleotide therapy. AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; GGT: γ-glutamyl transpeptidase; ALT: Alanine aminotransferase.